14-06-2012: Researchers in France and Sweden have discovered how one of the body’s own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, are reported in The EMBO Journal.
“We are fortunate to have a wide range of technologies that allow us to look more precisely at the molecular events that lead to the onset of chronic pain in animals,” said Marc Landry, lead author of the study and Professor at the University of Bordeaux. “Our results show that the levels of the naturally occurring protein 14-3-3 zeta are higher in the spinal cord of rats that have chronic pain. Moreover, we have been able to demonstrate how 14-3-3 zeta triggers changes in the signalling pathway that leads to the symptoms of chronic pain.”
The 14-3-3 zeta protein disrupts the interaction between the two subunits of the GABAB receptor, a protein complex found on the surface of nerve cells. GABAB receptors are G-protein coupled receptors, a family of receptors that regulate many physiological processes and which are frequently targeted for drug development.
The researchers used antibody labelling and microscopy techniques to investigate the molecular interactions of the signalling proteins. In cells and living animals, they were able to show that the 14-3-3 zeta protein interacts directly with the B1 subunit of the GABAB receptor. This interaction impairs the effective signalling of the receptor and limits the pain-relieving effects of the GABAB receptor under conditions of chronic pain.
The researchers also showed that the treatment of rats with a specific small interfering RNA (siRNA) or a competing peptide, molecules that interfere with the action of the 14-3-3 zeta protein, inhibited chronic pain.
“The impairment of the GABAB receptor by 14-3-3 zeta is a novel mechanism for the modulation of chronic pain,” said Landry. “We see potential in combining the use of inhibitors that interfere with the action of 14-3-3 zeta together with existing drug treatments like Baclofen for chronic pain. Targeting the GABAB dissociation process may be of therapeutic interest since it may allow classical pain killers to be more effective.”
Original publication: S. Laffray, R. Bouali-Benazzouz, M.-A. Papon, A. Favereaux, Y. Jiang, T. Holm, C. Spriet, P. Desbarats, P. Fossat, Y. Le Feuvre, M. Decossas, L. Héliot, U. Langel, F. Nagy, M. Landry; "Impairment of GABAB receptor dimer by endogenous 14-3-3 zeta in chronic pain conditions";
EMBO announced that 52 outstanding researchers in the life sciences were newly elected to its membership. Forty-three of the researchers reside in Europe and neighboring countries and are accompanied by the election of nine Associate Members from Canada, China, India, Japan and the United S ... more
How do you compare the impact of a researcher in chemistry or physics with a molecular biologist who may be working on similar projects? Two experts support the use of citation indicators that are based on percentiles, a statistical parameter that allows for comparisons with a carefully def ... more
Researchers have discovered proteins in human urine that offer new opportunities for the diagnosis, study and maybe even the treatment of Kawasaki disease. Mass spectrometry-based proteomic analysis of the human urine proteome, the entire set of proteins found in human urine, uncovered mole ... more
The European Molecular Biology Organization (EMBO) promotes excellence in molecular life sciences in Europe. Since 1964, leading scientists are elected annually to become EMBO Members based on proven excellence in research. Members number more than 1300 today with a further 80 associat ... more
More about Université Bordeaux
351 cours de la Libération
Researchers in France and Sweden have discovered how one of the body’s own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, are reported in The EMBO Journal.“We are fortunate to have a wide ran ... more